Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
暂无分享,去创建一个
J. Kosek | S. Surapaneni | P. Schafer | J. Reyes | M. Hoffmann | C. Kasserra | H. Kim-Kang | L. Capone | A. Parton | Gondi N. Kumar
[1] S. Surapaneni,et al. Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects , 2011, Cancer Chemotherapy and Pharmacology.
[2] Lei Wu,et al. Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis , 2010, British journal of pharmacology.
[3] R. Obach,et al. Physicochemical determinants of human renal clearance. , 2009, Journal of medicinal chemistry.
[4] A. Dalgleish,et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Rodrigues Ad,et al. Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .
[6] S. Mchugh,et al. Thalidomide and derivatives: immunological investigations of tumour necrosis factor‐alpha (TNF‐α) inhibition suggest drugs capable of selective gene regulation , 1997, Clinical and experimental immunology.
[7] M. Frech,et al. Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding , 2012, Leukemia.
[8] L. Sapinoso,et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. , 2010, Current cancer drug targets.
[9] A. D. Rodrigues,et al. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. , 1999, Biochemical pharmacology.